Cargando…

PD-L1 expression in breast cancer brain metastases

BACKGROUND: To evaluate the potential intracranial efficacy of immunotherapy among patients with breast cancer brain metastases (BrM), we analyzed the immunohistochemical expression of programmed death-ligand 1 (PD-L1), a predictive biomarker of response to immunotherapy. METHODS: In this single-cen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chehade, Rania, Qazi, Maleeha A, Ennis, Marguerite, Sahgal, Arjun, Das, Sunit, Nofech-Mozes, Sharon, Jerzak, Katarzyna J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Clinical Investigations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587695/ https://www.ncbi.nlm.nih.gov/pubmed/36299795 http://dx.doi.org/10.1093/noajnl/vdac154

Ejemplares similares

Androgen Receptor Is Expressed in the Majority of Breast Cancer Brain Metastases and Is Subtype-Dependent
por: Fan, Kevin Yijun, et al.
Publicado: (2023)

61. EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASIS
por: Qazi, Maleeha, et al.
Publicado: (2020)

EXPRESSION OF ANDROGEN RECEPTOR IN BREAST CANCER BRAIN METASTASES
por: Fan, Kevin Yijun, et al.
Publicado: (2023)

HER2-LOW BREAST CANCER BRAIN METASTASES: INCIDENCE AND TREATMENT IMPLICATIONS
por: Chehade, Rania, et al.
Publicado: (2023)

Incidence and real-world burden of brain metastases from solid tumors and hematologic malignancies in Ontario: a population-based study
por: Habbous, Steven, et al.
Publicado: (2020)

Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada
por: Wang, Xin Ye, et al.
Publicado: (2022)

Association of Brain Metastases With Survival in Patients With Limited or Stable Extracranial Disease: A Systematic Review and Meta-analysis
por: Li, Alyssa Y., et al.
Publicado: (2023)

Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases
por: Soliman, Hany, et al.
Publicado: (2016)

Karnofsky Performance Status (KPS) ≤60 Is Strongly Associated With Shorter Brain-Specific Progression-Free Survival Among Patients With Metastatic Breast Cancer With Brain Metastases
por: Freeman, Mark, et al.
Publicado: (2022)

Intracranial Metastatic Disease: Present Challenges, Future Opportunities
por: Li, Alyssa Y., et al.
Publicado: (2022)

Control and Toxicity in Melanoma Versus Other Brain Metastases in Response to Combined Radiosurgery and PD-(L)1 Immune Checkpoint Inhibition
por: Travis, Roman L., et al.
Publicado: (2020)

HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis
por: Erickson, Anders W, et al.
Publicado: (2020)

Editorial: Contemporary Management of Intracranial Metastatic Disease
por: Das, Sunit, et al.
Publicado: (2019)

Epidemiology of synchronous brain metastases
por: Singh, Raj, et al.
Publicado: (2020)

Hypofractionated Stereotactic Radiotherapy in Five Daily Fractions for Post-Operative Surgical Cavities in Brain Metastases Patients with and without Prior Whole Brain Radiation
por: Al-Omair, Ameen, et al.
Publicado: (2013)

Commentary: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
por: Das, Sunit, et al.
Publicado: (2020)

Survival in melanoma brain metastases in the era of novel systemic therapies
por: Merola, Joseph P, et al.
Publicado: (2020)

Subtype switching in breast cancer brain metastases: a multicenter analysis
por: Hulsbergen, Alexander F C, et al.
Publicado: (2020)

Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
por: Berghoff, Anna Sophie, et al.
Publicado: (2020)

Phase II multicenter trial combining nivolumab and radiosurgery for NSCLC and RCC brain metastases
por: Wong, Philip, et al.
Publicado: (2023)

MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening—A Critical Appraisal
por: Plotkin, Anna, et al.
Publicado: (2023)

The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases
por: Fujita, Yuya, et al.
Publicado: (2020)

Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases
por: Nilsen, Line Brennhaug, et al.
Publicado: (2020)

Outcome comparison of patients who develop leptomeningeal disease or distant brain recurrence after brain metastases resection cavity radiosurgery
por: Teyateeti, Achiraya, et al.
Publicado: (2021)

Dynamic susceptibility contrast MRI may contribute in prediction of stereotactic radiosurgery outcome in brain metastases
por: Starck, Lea, et al.
Publicado: (2022)

Automated detection and quantification of brain metastases on clinical MRI data using artificial neural networks
por: Pflüger, Irada, et al.
Publicado: (2022)

Collagen deposition within brain metastases is associated with leptomeningeal failure after  cavity-directed radiosurgery
por: Abdulhaleem, Mohammed, et al.
Publicado: (2023)

Advanced Magnetic Resonance Imaging Techniques in Management of Brain Metastases
por: Mehrabian, Hatef, et al.
Publicado: (2019)

A Dutch phase III randomized multicenter trial: whole brain radiotherapy versus stereotactic radiotherapy for 4–10 brain metastases
por: Hartgerink, Dianne, et al.
Publicado: (2021)

Feasibility and safety of cavity-directed stereotactic radiosurgery for brain metastases at a high-volume medical center
por: Rava, Paul, et al.
Publicado: (2016)

Efficacy of laser interstitial thermal therapy for biopsy-proven radiation necrosis in radiographically recurrent brain metastases
por: Chan, Michael, et al.
Publicado: (2023)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016
por: Brastianos, Harry C., et al.
Publicado: (2020)

A simple score to estimate the likelihood of pseudoprogression vs. recurrence following stereotactic radiosurgery for brain metastases: The Bergen Criteria
por: Skeie, Bente Sandvei, et al.
Publicado: (2020)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

A Cluster-then-label Semi-supervised Learning Approach for Pathology Image Classification
por: Peikari, Mohammad, et al.
Publicado: (2018)

Combination laser interstitial thermal therapy plus stereotactic radiotherapy increases time to progression for biopsy-proven recurrent brain metastases
por: Grabowski, Matthew M, et al.
Publicado: (2022)

Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study
por: Parker, Megan, et al.
Publicado: (2023)

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018)

Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study
por: Peled, Nir, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e4hq5oli9p8563obm63t2cef90